Immunomonitoring reveals interruption of anergy after vaccination in a case of type-2-papillary renal cell carcinoma
/in Dendritic Cells, Hypernephroma, International Publications /von 2017-03-01 / Immunotherapy 2017 03;9(4):319-329Safety, efficacy, and immunogenicity of autologous tumor lysate-pulsed dendritic cell vaccination therapy after resection of stage IIA (T2N0, T3N0) esophageal cancer: A phase I trial.
/in Dendritic Cells, Esophageal Carcinoma, International Publications /von 2017-02-23 / J Clin Oncol 35, 2017 (suppl 7S; abstract 153)Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study
/in Dendritic Cells, International Publications, Prostate Cancer /von 2017-02-15 / Cytotherapy 2017 04;19(4):500-513A Dendritic Cell Vaccine Combined With Radiotherapy Activates the Specific Immune Response in Patients With Esophageal Cancer
/in Dendritic Cells, Esophageal Carcinoma, International Publications /von 2017-02-01 / J. Immunother. 2017 Feb/Mar;40(2):71-76Immunotherapy for the treatment of multiple myeloma
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2017-01-27 / Crit. Rev. Oncol. Hematol. 2017 Mar;111:87-93Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
/in Dendritic Cells, International Publications, Prostate Cancer /von 2017-01-10 / Clin. Cancer Res. 2017 07;23(13):3352-3364Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2017-01-06 / Pharmacotherapy 2017 01;37(1):129-143Progress in Vaccine Therapies for Breast Cancer
/in Breast Cancer, Dendritic Cells, International Publications /von 2017-01-01 / Adv Exp Med Biol 2017;1026:315-330Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Multiple Myeloma /von 2017-01-01 / Curr Cancer Drug Targets 2017;17(9):782-805
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de